Secnidazole Microgranule Formulation Single-Dose Bacterial Vaginosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bacterial vaginosis often require multiple doses and have limitations in efficacy and safety compared to FDA-approved drugs, particularly for recurrent infections and pregnant women.
Innovation Solution
A microgranule formulation of secnidazole, which can be administered orally, providing a therapeutically effective dose in a single administration, combined with additional compounds like ethinyl estradiol or norethindrone, and mixed with food substances for improved bioavailability and tolerability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional treatments for bacterial vaginosis are used, then treatment options are available, but multiple doses are required and efficacy is limited
Solution Approach 1:
The patent divides the treatment into a single administered dose that releases secnidazole microgranules over time, segmenting the therapeutic action into controlled release phases rather than requiring multiple separate doses. This maintains high clinical cure rates while reducing the number of administration events.
Solution Approach 2:
The microgranule formulation provides continuous therapeutic action by releasing secnidazole gradually over an extended period (up to 14 days), ensuring sustained efficacy without requiring multiple discrete doses. This continuous release mechanism maintains effective drug concentrations throughout the treatment period.
2Reliability
If conventional treatments are used, then bacterial vaginosis can be treated, but safety concerns arise particularly for recurrent infections and pregnant women
Solution Approach 1:
The patent modifies the drug delivery parameters by using microgranule formulation with controlled release characteristics, changing the pharmacokinetic profile to improve safety. The extended release mechanism maintains lower peak concentrations while sustaining therapeutic levels, reducing side effects and improving safety for vulnerable populations including pregnant women and those with recurrent infections.
3Productivity
If secnidazole is administered in microgranule formulation, then single dose effectiveness is achieved, but formulation complexity increases
Solution Approach 1:
The patent employs composite material technology by combining secnidazole with excipients and coating materials to create microgranules with controlled release properties. This composite formulation approach enables single-dose effectiveness while managing the complexity through standardized pharmaceutical formulation techniques.
4Productivity
If secnidazole microgranule formulation is used, then clinical cure rate improves, but manufacturing precision requirements increase
Solution Approach 1:
The patent optimizes manufacturing parameters including particle size distribution, microgranule morphology, and coating thickness to achieve the desired release profile. By carefully controlling these parameters within specified ranges, the formulation achieves high clinical cure rates while managing manufacturing precision requirements through process optimization rather than extreme precision.
Data Source
AI summary
Embodiments are directed to a secnidazole formulations and the use of a secnidazole formulation for the treatment of bacterial vaginosis (BV).